Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134667
Status:
TERMINATED
Last Update Posted:
2007-01-15
First Post:
2005-08-24
Brief Title:
Macugen Pegaptanib Sodium Alone Versus Macugen in Combination With PDT Photodynamic Therapy With Visudyne Verteporfin in Patients With Age-Related Macular Degeneration AMD
Sponsor:
Eyetech Pharmaceuticals
Organization:
Eyetech Pharmaceuticals
Study Overview
Official Title:
A Phase IIIbIV Randomized Double-Masked Active Controlled Dose-Ranging Multi-Center Comparative Trial in Parallel Groups to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium Macugen Given Every 6 Weeks for 102 Weeks to Pegaptanib Sodium Plus Photodynamic Therapy PDT With Visudyne in Patients With Exudative Age-Related Macular Degeneration AMD
Status:
TERMINATED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the trial is to compare whether Macugen pegaptanib sodium in combination with PDT with Visudyne verteporfin is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None